As quality of life constantly improves, the average lifespan will continue to increase. Underlining this improvement is the vast amount of the UK government's support to NHS (£133.5 billion in year 2011/12) and the UK pharmaceutical industry's R&D large investment (4.9 billion to R&D in year 2011/12). The expectation of quality healthcare is inevitably high from all stakeholders. Fortunately recent advances in science and technology have enabled us to work towards personalised medicine and preventative care. This approach calls for a collective effort of researchers from a vast spectrum of specialised subjects. Advances in science and engineering is often accompanied by major development of mathematical sciences, as the latter underpin all other sciences. The UoL Centre will consist of a large and multidisciplinary team of applied and pure mathematicians, and statisticians together with healthcare researchers, clinicians and industrialists, collaborating with 15 HEIs and 40 NHS trusts plus other industrial partners and including our strongest groups: MRC Centre in Drug Safety Science, Centre for Cell imaging (CCI for live 3D and 4D imaging), Centre for Mathematical Imaging Techniques (unique in UK), Liverpool Biomedical EM unit, MRC Regenerative Medicine Hub, NIHR Health Protection Research Units, MRC Hub for Trials Methodology Research. Several research themes are highlighted below: Firstly, an improved understanding of the interaction dynamics of cells and tissues is crucial to developing effective future cures for cancer. Much of the current work is in 2D, with restrictive assumptions and without access to real data for modelling. We shall use the unparalleled real data of cell interactions in a 3D setting, generated at UoL's CCI. The real-life images obtained will have low contrast and noise and they will be analysed and enhanced by our imaging team through developing accurate and high resolution imaging models. The main imaging tools needed are segmentation methods (identifying objects such as cells and tissues regions in terms of sizes, shapes and precise boundaries). We shall propose and study a class of new 3D models, using our imaging data and analysis tools, to investigate and predict the spatial-temporal dynamics. Secondly, better models of how drugs are delivered to cells in tissues will improve personalised predictions of drug toxicity. We shall combine novel-imaging data of drug penetration into 3D experimental model systems with multi-scale mathematical models which scale-up from the level of cells to these model systems, with the ultimate aim of making better in-vitro to in-vivo predictions. Thirdly, there exist many competing models and software for imaging processing. However, for real images that have noise and are of low contrast, few methods are robust and accurate. To improve the modelling, applied and pure mathematicians team up to consider using more sophisticated tools of hyperbolic geometry and Riemann surfaces and fractional calculus to meet the demand for accuracy, and, applied mathematicians and statisticians will team up to design better data fidelity terms to model image discrepancies. Fourthly, resistance to current antibiotics means that previously treatable diseases are becoming deadly again. To understand and mitigate this, a better understanding is needed for how this resistance builds up across the human interaction networks and how it depends on antibiotic prescribing practices. To understand these scenarios, the mathematics competition in heterogeneous environments needs to be better understood. Our team links mathematical experts in analysing dynamical systems with experts in antimicrobial resistance and GPs to determine strategies that will mitigate or slow the development of anti-microbial resistance. Our research themes are aligned with, and will add value to, existing and current UoL and Research Council strategic investments, activities and future plans.

Radiotherapy plays an essential role in cancer treatment. There are various types of therapy that are used to target differing organs and cancers. One such type is Molecular radiotherapy (MRT). In this treatment, patients are administered with a radioactive solution, which has been specifically chosen to travel to the cancerous tissue. The radioactive solution emits radiation, which damages the cancerous cells in the tissue, with little damage to the surrounding healthy tissue. The most common use of MRT is for treatment of thyroid cancer and radioimmunotherapy, however it is not possible to provide personalised treatment plans to the level of traditional radiotherapy techniques. It is also not possible to measure the radiation dose delivered to the patient during the treatment, which means that knowledge of the impact of the treatment is limited. This research aims to develop an imaging system that can be used to assess the radiation dose delivered to the patient. It is based on traditional radiation imaging techniques used in hospitals but is tailored specifically for molecular radiotherapy of the thyroid. The research will lead to personalised treatment planning, which will reduce treatment costs and potentially increase rates of successful cancer treatment. Experts from the University of Liverpool and leading clinicians at the Royal Marsden and Royal Liverpool University Hospitals will conduct the research.

The IPS Fellow will coordinate the knowledge exchange strategy for Nuclear Physics, Particle Physics and Accelerator Science within the Department of Physics. Healthcare: The University of Liverpool, Department of Physics is one of only three national training providers for the new Modernising Scientific Careers (MSC) Medical Physics MSc, funded by the NHS. This was a highly successful bid, with Liverpool being ranked first against stiff competition. This MSc is delivered in collaboration with the Royal Liverpool University Hospital NHS Trust, the Clatterbridge Centre for Oncology (CCO) and Clinical Engineering with the University of Liverpool. The trainees come from throughout the UK. This provides a unique opportunity to build collaborative research and Continuing Professional Development (CPD) partnerships within the Healthcare sector. The fellow will coordinate these efforts and will help establish a new Medical Physics research institute within the University of Liverpool, which is a strategic goal of the University in its current planning. Security: The Fellow will help coordinate the exploitation of the sensor technology and associated instrumentation and techniques that exists within the research groups. The fellow will help consolidate existing relationships with partner organisations by showcasing the full breadth of STFC science activity. New opportunities for funding R+D will be identified together with establishing relationships with new companies. Energy: Liverpool scientists and engineers are working together as part of a new University Institute focused on research into energy. The Stephenson Institute is developing clean and sustainable energy technologies including hydrogen generation and storage, solar harvesting, wind and marine energy and fusion technology. The institute is in the process of developing expert networks, including policy-makers and management, to highlight global energy and sustainability issues. Making links with far eastern energy providers and attempting to attract a large investment from the University of Liverpool Energy campus we believe will be an important role of the fellow. The IPS Fellow will be fully engaged in this process, ensuring the opportunities for STFC science are fully exploited. The University of Liverpool Engineering, Electrical Engineering and Physics Departments are in the process of forming a Nuclear Engineering alliance which will maximise the exploitation of institutional expertise in autonomous systems, sensors and virtual engineering. The IPS Fellow will help coordinate the relationship between the alliance and external stakeholder organisations such as the National Nuclear Laboratory (NNL) and Sellafield Ltd. IT Developments: The Department was an early developer of large scale computing building the first large scale COTS cluster in n Europe in 2000 (MAP) and innovated specialized middleware . Subsequently the group invested in Grid computing and, at the same time founded the AiMeS Institute for commercial applications with NWDA and EW funding. This led to commercial spin-offs (AiMeS Grid Services) totally independent of the University currently delivering these Grid Services to the wider community. The Departments IT cluster activities, through also led to the introduction /choice of Force10 (now DELL) switches as the core switch technology at CERN; an example of beneficial relationship between industry and research. The group is now (separately from this request) bidding (with computer science partners) to develop a new generation of computers, based on a next generation of GPU chip and switch technology that aims to deliver a factor 1000:1 improvement in performance price of useable CPU cycles within the next decade. The IPS fellow will play a pivotal role in attracting commercial partners and carefully managing the IP issues that will arise.

This study will assess the impact on mental health of restricted access to arts and culture in a specific city region, and track, enable and enhance the value of innovation in arts provision in mitigating associated harms. Liverpool has one of the richest concentrations of culture in the UK, boasting the largest clustering of museums and galleries outside London. Cultural capital is critical to the city region's economy, contributing c10% (Culture Liverpool,2019). The city also has a pioneering history of harnessing arts for mental health care through partnerships between culture and health providers. Building on the University of Liverpool's strong alliance with organisations across these sectors, this project brings together an interdisciplinary team of arts and mental health researchers to devise and conduct, in consultation with cultural and health bodies, two surveys. Survey 1 (online interviews) will target 20 arts organisations (10 civic institutions, 10 community arts programmes, representing 'elite' and 'popular' arts) to capture (i)the impact of COVID-19 on public access to arts provision (including those who usually access the arts through formal healthcare routes) and on audience/beneficiary change over time (legacy losses and potential gains) (ii)the success of alternative (e.g. online/digital) modes of provision by arts organisations in reaching and communicating with established and/or new audiences. Survey 2 (online questionnaire and supplementary online/telephone interviews) will target c300 arts' audiences/beneficiaries to capture (i)the impact on mental health of restricted/non-existent access to usual provision (ii)the perceived value and accessibility of alternative arts provision and the latter's impact on mental health/wellbeing.

According to the World Health Organisation age-related macular degeneration (AMD) is the third most prevalent cause of blindness worldwide, and the leading cause of blindness in industrialised countries. There are two types, the neovascular - which contributes to 10% of cases - and atrophic - which contributes to 90% of cases. In AMD, a section of the retina called the Bruch's membrane thickens with age and can interfere with the waste/nutrient exchange between the retinal pigment epithelial (RPE) cells - the layer upon which photoreceptor cells attach and survive - and the choroid - the intricate network of vessels responsible for blood supply. This interference can cause the retinal pigment epithelial cells to die, which in turn can lead to photoreceptor cell death, eventually causing irreversible central vision loss. The sufferer loses their independence as this prevents them from carrying out everyday tasks such as reading and driving. The main risk factor for AMD is age and it, predominantly, affects people over the age of 50. It has already been reported by clinicians that cases of AMD have doubled between the years of 2000-2010, and with the population living longer the prevalence of this disease is anticipated to rise to more than double by the year 2030. Considering there is no current treatment for atrophic AMD and with its prevalence on the rise, this important issue needs to be addressed now. A number of studies report the use of substrates to deliver healthy RPE cells under the photoreceptor cells before they begin to die. They discuss placing the substrate on top of the diseased Bruch's membrane to deliver a monolayer of RPE cells. I believe that simply placing a novel substrate on top of the diseased membrane could exacerbate the issue. The problem in AMD is the thickened Bruch's membrane, so adding a further layer could further increase the nutrient/waste exchange path leading to damage to the transplanted cells. I hypothesise that a cell transplant substrate can be designed that will unblock the diseased Bruch's membrane while providing support for the healthy RPE monolayer thus leading to improved nutrient/waste exchange between the photoreceptors and the choroidal blood vessels. This project will develop a novel bioengineered persistent substrate with a bioactive layer that will deliver active molecules at a controlled rate. It will deliver the required monolayer of RPE cells in order to ensure photoreceptor cell survival while simultaneously removing and replacing the diseased native Bruch's membrane. These prerequisites address the necessity of having a permanent membrane upon which the retinal pigment epithelial cells can attach and survive, the removal of the diseased tissue, and the integration of the permanent substrate to replace the diseased Bruch's membrane in order to ensure that the optimal exchange pathway thickness is maintained. I believe this novel approach will contribute to improving quality of life by reducing the number of people who lose their independence and require assistance/intervention due to AMD. The project aligns to the key Life Sciences Industrial Strategy challenge of developing advanced therapeutics under the theme of healthy ageing in the Health Advanced Research Programme and contributes to the EPSRC Healthy Nation delivery plan ambitions.